Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi

Haematologica

Volumn 89, Issue 8, 2004, Pages 973-978

  Merli, Francesco ^a   Bertini, Marilena ^b   Luminari, Stefano ^c   Mozzana, Ruggero ^d   Bertè, Raffaella ^e   Trottini, Massimo ^f   Stelitano, Caterina ^g   Botto, Barbara ^b   Pizzuti, Michele ^h   Quintana, Gianni ⁱ   De Paoli, Alberto ^j   Federico, Massimo ^c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^e Ospedale Civile   (Italy)

^f POLICLINICO MONTELUCE   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h SAN CARLO HOSPITAL   (Italy)

ⁱ Divisione di Ematologia   (Italy)

^j Ospedale Civile di Legnano   (Italy)

more..

Author keywords

Elderly patients; Non Hodgkin's lymphoma; Quality of life

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE;

AGED; ANEMIA; APPETITE; ARTICLE; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; EMOTION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPETITE; BLEOMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; PAIN; PREDNISONE; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP; VINBLASTINE; VINCRISTINE;

EID: 3943053319     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-8.
3. th International Conference on Malignant Lymphoma, 2002.
4. Sonneveld P. The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens. Semin Oncol 1995;22 Suppl 1:29-31.
5. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.
6. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
7. Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999;94:33-8.
8. Merli F, Federico M, Avanzini P, Ilariucci F, Stelitano C, Iannitto E, et al. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. Haematologica 1998;83:217-21.
9. Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994;5:895-900.
10. Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:2362-9.
11. Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 1992;10:228-36.
12. th International Conference on Malignant Lymphoma. 2002.
13. Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology 1998;12:697-714.
14. Mounier N, Haioun C, Cole BF, Gisselbrecht C, Sebban C, Morel P, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Blood 2000;95:3687-92.
15. Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10:1079-86.
16. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology 1998;12:369-77.
17. Remick SC, Sedransk N, Haase RF, Blanchard CG, Ramnes CR, Nazeer T, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol 2001;66:178-88.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
19. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395-405.
20. Kopp M, Schweigkofler H, Holzner B, Nachbaur D, Niederwieser D, Fleischhacker WW, et al. EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison. Eur J Haematol 2000;65:97-103.
21. Fayers PM AN, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. 1995.
22. Wisloff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997;97:29-37.